Apurinic/apyrimidinic endonuclease 1 regulates inflammatory response in macrophages

Anticancer Research

Volumn 31, Issue 2, 2011, Pages 379-385

  Jedinak, Andrej ^a   Dudhgaonkar, Shailesh ^a   Kelley, Mark R ^b,c   Sliva, Daniel ^a,b,c  

^a METHODIST RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

APE1; Inflammatory response; Macrophages; Ref 1

Indexed keywords

ANTINEOPLASTIC AGENT; APURINIC APYRIMIDINE ENDONUCLEASE 1; CYCLOOXYGENASE 2; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; E 3330; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 6; LYASE INHIBITOR; NITRIC OXIDE; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; ENZYME INACTIVATION; IMMUNOREGULATION; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOQUINONES; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATION-REDUCTION; PROPIONIC ACIDS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953240211     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Fishel ML and Kelley MR: The DNA base excision repair protein APE1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med 28: 375-395, 2007. (Pubitemid 47331610)
2. Georgiadis M, Luo M, Gaur R, Delaplane S, Li X and Kelley MR: Evolution of the redox function in mammalian apurinic/apyrimidinic endonuclease. Mutat Res 643: 54-63, 2008.
3. Luo M, He H, Kelley MR and Georgiadis M: Redox regulation of DNA repair: implications for human health and cancer therapeutic development. Antioxid Redox Signal 12: 1247-1269, 2010.
4. Luo M, Delaplane S, Jiang A, Reed A, He Y, Fishel M, Nyland RL II, Borch RF, Qiao X, Georgiadis MM and Kelley MR: Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small molecule inhibition of Ape1's redox function. Antioxid Redox Signal 10: 1853-1867, 2008.
5. Bapat A, Fishel ML, Georgiadis M and Kelley MR: Going ape as an approach to cancer therapeutics. Antioxid Redox Signal 11: 651-668, 2009.
6. Bapat A, Glass LS, Luo M, Fishel ML, Long EC, Georgiadis MM and Kelley MR: Novel small molecule inhibitor of Ape1 endonuclease blocks proliferation and reduces viability of glioblastoma cells. J Pharmacol Exp Ther 334: 988-998, 2010.
7. Tell G, Quadrifoglio F, Tiribelli C and Kelley MR: The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal 11: 601-620, 2009.
8. Tell G, Zecca A, Pellizzari L, Spessotto P, Colombatti A, Kelley MR, Damante G and Pucillo C: An 'environment to nucleus' signaling system operates in B lymphocytes: redox status modulates BSAP/Pax-5 activation through Ref-1 nuclear translocation. Nucleic Acids Res 28: 1099-1105, 2000.
9. Zou GM and Maitra A: Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration. Mol Cancer Ther 7: 2012-2021, 2008.
10. Zou GM, Karikari C, Kabe Y, Handa H, Anders RA and Maitra A: The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis. J Cell Physiol 219: 209-218, 2009.
11. Jimeno A, Feldmann G, Suárez-Gauthier A, Rasheed Z, Solomon A, Zou GM, Rubio-Viqueira B, García-García E, López-Ríos F, Matsui W, Maitra A and Hidalgo M: A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 8: 310-314, 2009.
12. Hofseth LJ, Khan MA, Ambrose M, Nikolayeva O, Xu-Welliver M, Kartalou M, Hussain SP, Roth RB, Zhou X, Mechanic LE, Zurer I, Rotter V, Samson LD and Harris CC: The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest 112: 1887-1894, 2003.
13. Lee HM, Yuk JM, Shin DM, Yang CS, Kim KK, Choi DK, Liang ZL, Kim JM, Jeon BH, Kim CD, Lee JH and Jo EK: Apurinic/apyrimidinic endonuclease 1 is a key modulator of keratinocyte inflammatory responses. J Immunol 183: 6839-6848, 2009.
14. Laskin DL and Pendino KJ: Macrophages and inflammatory mediators in tissue injury. Annu Rev Pharmacol Toxicol 35: 655-677, 1995.
15. Hawiger J: Innate immunity and inflammation: a transcriptional paradigm. Immunol Res 23: 99-109, 2001.
16. Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183, 2007.
17. Balkwill F, Charles KA and Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217, 2005. (Pubitemid 40568680)
18. Bingle L, Brown NJ and Lewis CE: The role of tumor-associated macrophages in tumor progression: implication for new anticancer therapies. J Pathol 196: 254-265, 2002. (Pubitemid 34189413)
19. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC and Gascoyne RD: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362: 875-885, 2010.
20. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR and Binder C: Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 25: 1543-1549, 2004.
21. Lin CY, Lin CJ, Chen KH, Wu JC, Huang SH and Wang SM: Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction. FEBS Lett 580: 3042-3050, 2006.
22. Kimura YN, Watari K, Fotovati A, Hosoi F, Yasumoto K, Izumi H, Kohno K, Umezawa K, Iguchi H, Shirouzu K, Takamori S, Kuwano M and Ono M: Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci 98: 2009-2018, 2007.
23. Lawrence T, Willoughby DA and Gilroy DW: Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nature Rev Immunol 2: 787-795, 2002. (Pubitemid 37328718)
24. Kaplanski G, Marin V, Montero-Julian F, Mantovani A and Farnarier C: IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 24: 25-29, 2003. (Pubitemid 35462110)
25. Bosca L, Zeini M, Traves PG and Hortelano S: Nitric oxide and cell viability in inflammatory cells: a role for NO in macrophage function and fate. Toxicology 208: 249-258, 2005. (Pubitemid 40187335)
26. Lapa e Silva JR, Possebon da Silva MD, Lefort J and Vargaftig BB: Endotoxins, asthma, and allergic immune responses. Toxicology 152: 31-35, 2000.
27. Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchieri G and Kim TS: Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J Biol Chem 275: 32681-32687, 2000.
28. Bogdan C: Nitric oxide and the immune response. Nature Immunol 2: 907-916, 2001.
29. Harris SG, Padilla J, Koumas L, Ray D and Phipps RP: Prostaglandins as modulators of immunity. Trends Immunol 23: 144-150, 2002. (Pubitemid 34178297)
30. Takeda K and Akira S: Toll-like receptors in innate immunity. Int Immunol 17: 1-14, 2005.
31. Aderem A and Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 406: 782-787, 2000.
32. Shen H, Tesar BM, Walker WE and Goldstein DR: Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J Immunol 181: 1849-1858, 2008.
33. Medvedev AE, Piao W, Shoenfelt J, Rhee SH, Chen H, Basu S, Wahl LM, Fenton MJ and Vogel SN: Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance. J Biol Chem 282: 16042-16053, 2007. (Pubitemid 47100380)
34. Murphy TL, Cleveland MG, Kulesza P, Magram J and Murphy KM: Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol7 Cell Biol 15: 5258-5267, 1995.
35. Zhu C, Gagnidze K, Gemberling JH and Plevy SE: Characterization of an activation protein-1-binding site in the murine interleukin-12 p40 promoter. Demonstration of novel functional elements by a reductionist approach. J Biol Chem 276: 18519-18528, 2001.
36. Cho HJ, Seon MR, Lee YM, Kim J, Kim JK, Kim SG and Park JHY: 3,3′-Diindolylmethane suppresses the inflammatory response to lipopolysaccharide in murine macrophages. J Nutr 138: 17-23, 2008.
37. Kelley MR, Luo M, Reed A, Su D, Delaplane S, Borch R, Nyland RL, Gross ML and Georgiadis M: Functional analysis of new and novel analogs of E3330 that block the redox signaling activity of the multifunctional AP endonuclease/redox signaling enzyme APE1/Ref-1. Antioxid Redox Signal [Epub ahead of print], Jan 4, 2011.
38. Nyland RL, Luo M, Kelley MR and Borch RF: Design and synthesis of novel quinone inhibitors targeted to the redox function of apurinic/apyrimidinic endonuclease 1/redox enhancing factor-1 (Ape1/Ref-1). J Med Chem 53: 1200-1210, 2010.
39. Dudhgaonkar S, Thyagarajan A and Sliva D: Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum. Int Immunopharmacol 9: 1272-1280, 2009.
40. Nishi T, Shimizu N, Hiramoto M, Sato I, Yamaguchi Y, Hasegawa M, Aizawa S, Tanaka H, Kataoka K, Watanabe H and Handa H: Spatial redox regulation of a critical cysteine residue of NF-kappa B in vivo. J Biol Chem 277: 44548-44556, 2002. (Pubitemid 36157890)
41. Xanthoudakis S, Miao G, Wang F, Pan YC and Curran T: Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J 11: 3323-3335, 1992.
42. Miyamoto K, Nagakawa J, Hishinuma I, Hirota K, Yasuda M, Yamanaka T, Katayama K and Yamatsu I: Suppressive effects of E3330, a novel quinone derivative, on tumor necrosis factor-alpha generation from monocytes and macrophages. Agents Actions 37: 297-304, 1992. (Pubitemid 23062760)
43. Goto M, Yamada K, Katayama K and Tanaka I: Inhibitory effect of E3330, a novel quinone derivative able to suppress tumor necrosis factor-alpha generation, on activation of nuclear factor-kappa B. Mol Pharmacol 49: 860-873, 1996. (Pubitemid 26149911)
44. Nagakawa J, Hishinuma I, Miyamoto K, Hirota K, Abe S, Yamanaka T, Katayama K and Yamatsu I: Protective effects of (2E)-3-[5-(2,3-dimethoxy-6- methyl-1,4-benzoquinoyl)]-2-nonyl-2-propenoic acid on endotoxin-mediated hepatitis in mice. J Pharmacol Exp Ther 262: 145-150, 1992.
45. Nanji AA, Sadrzadeh SM, Khettry U, Thomas P and Yamanaka T: Protective effects of a novel quinone derivative, (2E)-3-[5-(23 dimethoxy-6-methyl-1,4- benzoquinoyl)]-2-nonyl-2-propanoic acid on experimental alcoholic liver injury. J Pharmacol Exp Ther 266: 1085-1090, 1993. (Pubitemid 23318728)
46. Evans AR, Limp-Foster M and Kelley MR: Going APE over ref-1. Mutat Res 461: 83-108, 2000.
47. Jiang Y, Zhou S, Sandusky GE, Kelley MR and Fishel ML: Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression. Cancer Invest 28: 885-895, 2010.
48. Fishel ML, Colvin ES, Luo M, Kelley MR and Robertson KA: Inhibition of the redox function of APE1/Ref-1 in myeloid leukemia cell lines result in enhanced sensitivity to retinoic acid-induced differentiation and apoptosis. Exp Hematol 38: 1178-1188, 2010.
49. Jiang Y, Guo C, Fishel ML, Wang ZY, Vasko MR and Kelley MR: Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small-molecule inhibitors to delineate APE1 functions. DNA Repair 8: 1273-1282, 2009.
50. Saitou Y, Shiraki K, Yamanaka T, Miyashita K, Inoue T, Yamanaka Y, Yamaguchi Y, Enokimura N, Yamamoto N, Itou K, Sugimoto K and Nakano T: Augmentation of tumor necrosis factor family-induced apoptosis by E3330 in human hepatocellular carcinoma cell lines via inhibition of NF kappa B. World J Gastroenterol 11: 6258-6261, 2005. (Pubitemid 43013991)
51. Curtis CD, Thorngren DL, Ziegler YS, Sarkeshik A, Yates JR and Nardulli AM: Apurinic/apyrimidinic endonuclease 1 alters estrogen receptor activity and estrogen-responsive gene expression. Mol Endocrinol 23: 1346-1359, 2009.
52. Meng Y, Beckett MA, Liang H, Mauceri HJ, van Rooijen N, Cohen KS and Weichselbaum RR: Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res 70: 1534-1543, 2010.
53. Quails JE and Murray PJ: A double agent in cancer: stopping macrophages wounds tumors. Nature Med 16: 863-864, 2010.
54. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A and Brown JM: Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci USA 107: 8363-8368, 2010.